Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on pregabalin for generalized anxiety disorder comorbid with major depressive disorder
2012-004062-17Phase 4Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in generalized anxiety disorder (GAD) and major depressive disorder (MDD) comparing Escitalopram + pregabalin with Escitalopram + placebo (2 arms). Primary endpoints: Change in STAI-S score and Change in Trail Making Test-B performance. Started May 2013; status: completed.
02
Drugs
pregabalin
03
Conditions
generalized anxiety disorder (GAD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2012-004062-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004062-17.